Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408885 | 1.00 | KMT2A (0.52) | KMT2ADAOMAOBKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL3902582 | 0.98 | KMT2A (0.50) | KMT2ADAOMAOBKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL23572864 | 0.98 | KMT2A (0.50) | KMT2ADAOMAOBKDM1AMAOA | |
| Sulfuric Acid SCHEMBL28396016 | 0.89 | KMT2A (0.51) | KMT2ADAOMAOBKDM1AMAOA | |
| Acetic Acid SCHEMBL28400640 | 0.88 | KMT2A (0.54) | KMT2ADAOMAOBKDM1AMAOA | |
| SCHEMBL264652 | 0.84 | TAAR1 (0.52) | KMT2ADAOMAOBKDM1AMAOA | |
| SCHEMBL31477886 | 0.84 | TAAR1 (0.52) | KMT2ADAOMAOBKDM1AMAOA | |
| SCHEMBL11951542 | 0.83 | KMT2A (0.50) | KMT2ADAOMAOBKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL2130617 | 0.82 | TAAR1 (0.50) | KMT2ADAOMAOBKDM1AMAOA | |
| SCHEMBL485439 | 0.79 | KMT2A (0.47) | KMT2ADAOMAOBKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777008-A | Preparation method of 2-aminomethyl-5-trifluoromethyl pyridine | 天津均凯农业科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-111170932-A | Preparation method of 2-aminomethyl-5-trifluoromethyl pyridine salt | 大连九信精细化工有限公司 | 2020-05-19 | — | — | CN | claimed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| JP-7025853-A | — | — | None | — | — | JP | disclosed |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025068985-A1 | 1-(1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025039979-A1 | PROTEIN ARGININE METHYLTRANSFERASE-5 INHIBITOR AND PHARMACEUTICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-118359617-A | Protein arginine methyltransferase inhibitors | 华润医药研究院（深圳）有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| JP-H0725853-A | AMIDO COMPOUND OR ITS SALT, ITS PRODUCTION AND CONTROLLER FOR HARMFUL ANIMAL CONTAINING THE SAME | ISHIHARA SANGYO KAISHA LTD | 1995-01-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | KMT2A 2802/4885DAO 2997/4885MAOB 1110/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | KMT2A 1047/4885DAO 4086/4885MAOB 2540/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | KMT2A 2463/4885DAO 729/4885MAOB 157/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | KMT2A 3390/4885DAO 1025/4885MAOB 189/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KMT2A 4179/4885DAO 4161/4885MAOB 1447/4885 |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT6 | KMT2A 43/4885DAO 2651/4885MAOB 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.